During Monday’s Current trade, Shares of Mohawk Industries, Inc. (NYSE:MHK), gain 1.06% to $206.01.
Mohawk Industries, Inc. (MHK) declared 2015 second quarter net earnings of $186 million and diluted earnings per share (EPS) of $2.53. Not taking into account unusual charges, net earnings were $199 million and EPS was $2.69, a 22% enhance over last year’s second quarter adjusted EPS and the highest adjusted quarterly EPS in the company’s history. Net sales for the second quarter of 2015 were $2.0 billion, flat as compared to the preceding year’s second quarter or a 7% enhance on a constant currency exchange rate basis. For the second quarter of 2014, net sales were $2.0 billion, net earnings were $153 million and EPS was $2.08; not taking into account unusual charges, net earnings were $162 million and EPS was $2.21.
For the six months ending July 4, 2015, net sales were $3.92 billion, an enhance of about 2% as compared to preceding year or an enhance of about 9% on a constant currency exchange rate basis. Net earnings and EPS for the six-month period were $209 million and $2.83, respectively. Net earnings not taking into account unusual charges were $324 million and adjusted EPS was $4.39, an enhance of 28% over the six-month period adjusted EPS result in 2014. For the six-months ending June 28, 2014, net sales were $3.86 billion, net earnings were $234 million and EPS was $3.19; not taking into account unusual charges, net earnings and EPS were $252 million and $3.44.
Mohawk Industries, Inc. designs, manufactures, sources, distributes, and markets flooring products for residential and commercial applications for remodeling and new constructions worldwide. It operates in three segments: Carpet, Ceramic, and Laminate and Wood. The Carpet segment offers carpet and rug product lines in a range of colors, textures, and patterns for residential and commercial applications; and markets and distributes ceramic tiles, laminate, hardwood, resilient floor coverings, carpet pads, and flooring accessories. This segment markets and distributes its flooring products under the Aladdin, Bigelow, Durkan, Horizon, Karastan, Lees, Mohawk, Mohawk ColorCenters, Mohawk Floorscapes, Mohawk Home, Portico, and SmartStrand brands.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX), declined -3.75% to $6.03, during its current trading session.
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, declared its financial results for the second quarter ended June 30, 2015.
BUSINESS HIGHLIGHTS
Auryxia U.S. Commercialization
- Net U.S. Auryxia product sales for the second quarter were about $1.8 million, based on about 3,700 Auryxia prescriptions, as stated to the company by IMS Health and specialty pharmacies that do not report data to IMS, counting DaVita Rx and Fresenius Rx.
- Unrestricted access for Auryxia raised to 65 percent across Medicare Part D and commercial insurance providers, with the addition of Auryxia on the formularies of two national Part D insurance providers that began processing claims in the third quarter of 2015.
- Keryx’s sales representatives have reached more than 75 percent of the 5,000 prescriber targets; about 1,000 target prescribers have written a prescription for Auryxia.
- Keryx successfully introduced samples into the market in the second quarter, with about 6,000 starter kits shipped to about 1,300 target prescribers — the majority of whom had not formerly prescribed Auryxia.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis.
American Capital Agency Corp. (NASDAQ:AGNC), during its Monday’s current trading session gained 0.1% to $19.25.
merican Capital Agency Corp. (AGNC) stated a comprehensive loss for the second quarter of 2015 of $(0.97) per common share and net book value of $24.00 per common share. Economic loss for the period, defined as dividends per common share and the change in net book value (“NAV”) per common share, was -3.6% for the quarter, or -14.3% on an annualized basis.
SECOND QUARTER 2015 FINANCIAL HIGHLIGHTS
- $(0.97) comprehensive loss per common share, comprised of:
- $1.43 net income per common share
- $(2.40) other comprehensive loss (“OCI”) per common share
- Comprises net unrealized losses on investments marked-to-market through OCI
- $0.60 net spread and dollar roll income per common share, not taking into account estimated “catch-up” premium amortization benefit
- Comprises $0.15 per common share of dollar roll income associated with the Company’s $6.0 billion average net long position in forward purchases and sales of agency mortgage-backed securities (“MBS”) in the “to-be-declared” (“TBA”) market
- prepayment rate (“CPR”) estimates
American Capital Agency Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by government-sponsored enterprise or by the United States government agency. It funds its investments primarily through short-term borrowings structured as repurchase agreements.
Finally, Halozyme Therapeutics, Inc. (NASDAQ:HALO), gained 3.34%, to $21.79.
Halozyme Therapeutics, Inc. (HALO) declared the Pancreas Center at the University of California, San Francisco (UCSF) has initiated a clinical research study of Halozyme’s investigational new drug, PEGPH20 in pancreatic cancer patients who are candidates for potentially curative surgery. The trial will be conducted within the UCSF Helen Diller Family Comprehensive Cancer Center.
The Phase 2 study will investigate PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE) in patients with borderline resectable Pancreatic Ductal Adenocarcinoma (PDAC). The study will track the progress of up to 36 patients through chemotherapy and surgical treatment.
PEGPH20 (PEGylated recombinant human hyaluronidase) targets the degradation of hyaluronan (HA), a chain of natural sugars that can accumulate around cancer cells, inhibiting other therapies. By degrading HA, PEGPH20 may enhance the access of co-administered chemotherapeutic and immunotherapeutic agents.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.